February 19th 2024
Sarah Sammons, MD, discusses research efforts in breast cancer focused on HER2-directed therapeutic approaches with central nervous system activity.
February 16th 2024
The sNDA for enfortumab vedotin-ejfv plus pembrolizumab in patients with metastatic urothelial cancer has received priority review in Japan.
The FDA has granted clearance for the first real-time, non-invasive skin cancer evaluation system .
February 15th 2024
Burton Eliot Appel, MD, discusses the landscape of pediatric oncology on International Childhood Cancer Day.
Sarah Sammons, MD, discusses what is known about the incidence of brain metastases in patients with breast cancer.
Joshua K. Sabari, MD, discusses updates in ADCs in NSCLC.
February 14th 2024
Joshua K. Sabari, MD, explains the utility of ADCs in patients with NSCLC and their benefit in patients with EGFR-, ALK-, or HER2-mutant disease.
February 13th 2024
CAN-3110, an HSV-1 oncolytic viral immunotherapy candidate, has received FDA fast track designation for adult patients with recurrent high-grade glioma.
February 8th 2024
Teclistamab produced responses in real-world patients with relapsed and refractory multiple myeloma and prior exposure to BCMA-targeted therapy.
HPN328, was well tolerated and elicited responses in patients with neuroendocrine prostate cancer and other neuroendocrine neoplasms.
February 7th 2024
Survival outcomes following curative resection in resectable NSCLC have been poor and, until recently, the main tool oncologists had at their disposal was neoadjuvant or adjuvant chemotherapy.
Edgardo S. Santos Castillero, MD, FACP, spotlights some impactful trials in lung cancer that were discussed in 2023, including the phase 3 MARIPOSA-2 trial, and more.
February 6th 2024
Edgardo S. Santos Castillero, MD, FACP, expands on outcomes from pivotal phase 3 trials such as ADAURA and FLAURA2 in patients with EGFR-mutant NSCLC.
February 5th 2024
The UV1 cancer vaccine received fast track designation for use in combination with ipilimumab and nivolumab for patients with unresectable malignant pleural mesothelioma.
February 4th 2024
World Cancer Day is held every year on February 4th, prompting individuals across the globe to expand awareness within cancer care.
February 3rd 2024
Hans Lee, MD, discusses updated data from the LINKER-MM1 study in heavily pretreated relapsed/refractory multiple myeloma.
February 2nd 2024
Lenvatinib/pembrolizumab demonstrated efficacy irrespective of tumor burden in advanced renal cell carcinoma in the overall patient population of the phase 3 CLEAR study.
February 1st 2024
The FDA has accepted for priority review the BLA seeking the approval of afamitresgene autoleucel for the treatment of advanced synovial sarcoma.
January 29th 2024
Momelotinib gets market authorization from the European Commission for patients with MPNs and disease-related splenomegaly or moderate to severe anemia.
CD19 CAR T cell therapy plus acalabrutinib demonstrated early efficacy in patients with relapsed/refractory mantle cell lymphoma.